(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 April 2012 (12.04.2012)

PCT

(10) International Publication Number
WO 2012/047538 A1

(51) International Patent Classification:
A01N 43/52 (2006.01) *A61K 31/4164* (2006.01)

(21) International Application Number:
PCT/US2011/052857

(22) International Filing Date:
23 September 2011 (23.09.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/390,314 6 October 2010 (06.10.2010) US
61/528,397 29 August 2011 (29.08.2011) US

(71) Applicant *(for all designated States except US)*: **GLAXOSMITHKLINE LLC** [US/US]; One Franklin Plaza, 200 N. 16th Street, Philadelphia, Pennsylvania 19102 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **QU, Junya** [CN/US]; c/o GlaxoSmithKline, Global Patents Department, 1250 South Collegeville Road, P. O. Box 5089, Collegeville, Pennsylvania 19426 (US). **RIVERO, Ralph** [US/US]; c/o GlaxoSmithKline, Global Patents Department, 1250 South Collegeville Road, P. O. Box 5089, Collegeville, Pennsylvania 19426 (US). **SANCHEZ, Robert** [US/US]; c/o GlaxoSmithKline, Global Patents Department, 1250 South Collegeville Road, P. O. Box 5089, Collegeville, Pennsylvania 19426 (US). **TEDESCO, Rosanna** [IT/US]; c/o GlaxoSmithKline, Global Patents Department, 1250 South Collegeville Road, P. O. Box 5089, Collegeville, Pennsylvania 19426 (US).

(74) Agents: **YOUNG, J. Scott** et al.; c/o GlaxoSmithKline, Global Patents Department, Five Moore Drive, P. O. Box 13398, Research Triangle Park, North Carolina 27709 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS

(57) Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3' OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective benzimidazoles compounds for treating cancer.

WO 2012/047538 A1